{"id":"amoxicillin-pulsatile-release-multiparticluate-sprinkle","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin works by disrupting peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. The pulsatile release multiparticulate sprinkle formulation is designed to deliver the drug in a controlled, time-dependent manner rather than continuous release, potentially optimizing therapeutic levels and reducing dosing frequency. This formulation approach may improve patient compliance and reduce gastrointestinal side effects.","oneSentence":"Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, delivered via a pulsatile release multiparticulate sprinkle formulation for modified pharmacokinetics.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:26.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections susceptible to amoxicillin (specific indications in Phase 3 development unknown)"}]},"trialDetails":[{"nctId":"NCT00100126","phase":"PHASE3","title":"APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat","status":"COMPLETED","sponsor":"Advancis Pharmaceutical Corporation","startDate":"2004-12","conditions":"Pharyngitis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","genericName":"Amoxicillin Pulsatile Release Multiparticluate Sprinkle","companyName":"Advancis Pharmaceutical Corporation","companyId":"advancis-pharmaceutical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, delivered via a pulsatile release multiparticulate sprinkle formulation for modified pharmacokinetics. Used for Bacterial infections susceptible to amoxicillin (specific indications in Phase 3 development unknown).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}